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Abstract
Copper is involved in different hallmarks of cancer, including metastasis, but responsible copper-binding proteins and path-
ways are not clear. The copper chaperone ATOX1 was recently shown to play a role in breast cancer cell migration, which is a 
key step in metastasis. Since most cancer-related deaths are due to metastasis, we hypothesized that ATOX1 mRNA expression 
may be associated with breast cancer disease progression and thus, a prognostic biomarker in breast cancer. We therefore 
studied the association of ATOX1 expression levels with clinicopathological parameters and survival for 1904 breast cancer 
patients using the METABRIC data set. Our results indicate ATOX1 expression levels as a potential prognostic biomarker 
for ER-positive subtypes and early stages of breast cancer. Pre-clinical studies and clinical trials are desired to identify the 
molecular roles of ATOX1 in these conditions.
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Introduction
Since copper (Cu) is a key component of many enzymes 
[1, 2], it is not surprising that Cu is required for at least 
three characteristic phenomena involved in cancer: prolif-
erative immortality, angiogenesis and metastasis. In support 
of increased Cu demand, cancer tissue and cancer patients’ 
serum have increased Cu levels [3] and breast cancers 
patients with distant metastasis were recently shown to have 
increased serum Cu levels [4].
Previously, we identified overexpressed Cu transport pro-
teins in cancer, through analysis of the RNA transcript level 
changes of the whole Cu proteome (i.e., for 54 identified 
Cu-binding proteins) in different cancer tissues using infor-
mation from The Cancer Genome Atlas, or TCGA, data-
base. Our analysis revealed that, with respect to ATOX1, it 
is upregulated in breast, colorectal, uterus and liver tumors, 
and the breast cancer data were confirmed by us in tissue 
microarray experiments [5]. Moreover, when imaging cells, 
we found ATOX1 to be localized at lamellipodia edges of 
aggressive breast cancer cells. This hinted to a role in cancer 
cell migration and, indeed, upon ATOX1 silencing, wound 
closure was reduced [6]. Since cancer metastasis consists 
of a cascade of processes that depends sensitively on cell 
migration this implies that ATOX1 may be important for 
processes facilitating metastasis [7]. Importantly, 90% of all 
cancer-related deaths are due to metastasis [8].
To assess the putative role of ATOX1 as a prognostic 
biomarker in breast cancer patients, we here investigated 
the correlation between ATOX1 mRNA expression levels 
and patient survival using the Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC) 
breast cancer database. METABRIC covers a large variety 
of breast cancers with long-term follow-up data, while other 
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large-scale data sets like TCGA are limited in the analysis of 
clinical associations by the scarcity of long-term patient fol-
low-up data and stringent criteria used for sample selection.
Materials and methods
METABRIC
Clinical data and ATOX1 mRNA expression z-scores were 
extracted from the METABRIC breast cancer study data-
base publicly available via cBioPortal website, https ://www.
cbiop ortal .org/ [9–11]. The mRNA expression scores were 
available for 1904 primary breast cancers, out of the total 
number of 2509 patients, with a maximum follow-up period 
of 355 months. Detailed information about tissue collection 
and staging is described by Curtis et al. [9].
Statistics
For data analysis cutoff was arbitrarily set at 10%, meaning 
“Low” are the bottom 10% and “high” are the top 10% of 
the patient cohort after sorting patients based upon ATOX1 
mRNA expression levels. Statistical analysis was per-
formed using SPSS software (IBM SPSS statistics version 
22). Patient survival was plotted using Kaplan–Meier (KM) 
curves with log-rank statistical test. The Chi-square test was 
used to analyze the correlation between clinicopathologi-
cal parameters and ATOX1 mRNA expression scores. COX 
proportional hazard model was applied to analyze the cor-
relation between clinicopathological parameters and disease-
specific survival (DSS).
Results
High ATOX1 expression is associated with poor 
survival of breast cancer patients
Upon survival analysis of all different breast cancer 
patients in the METABRIC cohort, we discovered that 
patients with high ATOX1 mRNA levels (10% of patients 
with highest ATOX1 mRNA levels, i.e., more than a 1.3-
fold increase above median) in their primary tumor have 
poorer survival than those with low ATOX1 mRNA levels 
(10% of patients with lowest ATOX1 mRNA levels, i.e., 
more than a 1.3-fold decrease below median) (median 
DSS is 130 months for low ATOX1 vs. 85 months for high 
ATOX1, p < 0.001, Fig. 1). Notably, the survival disadvan-
tage is maintained when comparing the 10% of patients 
with highest ATOX1 mRNA levels (n = 195) vs. all other 
90% of patients in the cohort (n = 1709) (Fig. S1). Thus, 
ATOX1 expression portends a survival disadvantage in 
breast cancer patients. Since survival is largely coupled 
to metastasis, high ATOX1 levels may report on increased 
occurrence of metastasis in those patients.
Follow-up time for the selected cohort (n = 390, i.e., 
lowest 10% and highest 10% merged) was up to 330 months 
with a median of 119 months and number of disease-spe-
cific events (i.e., breast cancer death) was 137 out of 390 
(35.1%) [death by other causes, 87 (22.3%)]. Other clinico-
pathological parameters that significantly variate between 
the low and high ATOX1 expression groups are menopau-
sal state (p = 0.024), histological grade (p = 0.044), lymph 
node status (p < 0.001), human epidermal growth factor 
receptor 2 (HER2) status (p < 0.001), estrogen receptor 
(ER) status (p = 0.023) and hormone therapy (p < 0.001) 
(Table S1). More, larger (> 2  cm) tumors (p = 0.017), 
histological grade 3 (p = 0.039), positive lymph nodes 
(p < 0.001), moderate and high cellularity (p < 0.001), and 
progesterone receptor (PR)-positivity (p = 0.001) corre-
late with worse disease-specific survival of patients in the 
selected cohort (Table S2). More, in Fig. S2 we present 
the number of patients with low (lowest 10%, n = 195) or 
high (highest 10%, n = 195) ATOX1 mRNA expression as 
a function of PAM50 molecular subtype and tumor stage. 
We also included the numbers of patients who received 
hormone therapy and/or chemotherapy.
Fig. 1  Patient survival depends on ATOX1 mRNA expression level. 
Disease-specific survival (DSS) KM curves for breast cancer patients 
stratified by ATOX1 expression. “Low” are the bottom 10% (n = 195) 
and “high” are the top 10% (n = 195) of the patient cohort (total 
n = 1904) after sorting patients based upon ATOX1 mRNA expression 
levels
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High ATOX1 levels relate with worse survival 
of patients with specific breast cancer subtypes
To obtain more detailed information on the role of ATOX1 
in breast cancer, we evaluated the correlation between 
ATOX1 expression levels and survival outcome for the dif-
ferent PAM50 molecular subtypes, plus the Claudin low 
molecular subtype (see Fig.S3A, B for KM curves for DSS 
of patients for different subtypes of breast cancer within the 
entire cohort (n = 1904) and the selected cohort (n = 390), 
respectively). The PAM50 subtypes of breast cancer are 
based upon patterns of gene expression (i.e., 50-gene sub-
type predictor) and are defined into five groups of Luminal 
A, Luminal B, HER2-enriched, Basal-like, and Normal-like 
[12].
We found a strong correlation between high ATOX1 
mRNA levels and reduced DSS for Normal-like (median 
DSS of 161  months for low ATOX1 vs. 64  months for 
high ATOX1, p = 0.005), Luminal A (171 vs. 91 months, 
p = 0.002) and Luminal B (158 vs. 67 months, p = 0.001) 
breast cancer subtypes. We found no significant correla-
tion between ATOX1 mRNA levels and patient survival 
for Basal-like (79 vs. 76 months), Claudin low (110 vs. 
105 months) and HER2-enriched cancer subtypes (106 vs. 
82 months) [Fig. 2, Fig. S4 shows overall survival (OS) KM 
plots]. This demonstrates that the ATOX1 expression level 
correlates with patient survival only in specific molecular 
subtypes of breast cancer.
High ATOX1 mRNA levels relate with worse 
prognosis for patients at early stages of disease
Next, we investigated ATOX1 expression vs. survival out-
come at different stages of breast cancer. While the pri-
mary tumor at stages 0 and 1 is localized, at stages 2 and 
3 the tumor shows increased regional spread to the lymph 
nodes [13]. Interestingly, we found the largest correlation 
between ATOX1 expression levels and disease-specific 
patient survival for stage 1 breast cancer tumors (median 
DSS of 164 months for low ATOX1 vs. 100 months for high 
ATOX1, p = 0.008), followed by a less significant correlation 
for stage 2 tumors (131 vs. 90 months, p = 0.018) and no 
correlation for stage 3 tumors (Fig. 3). Since the number of 
stage 3 cases was very small (n = 18) in the selected cohort, 
we additionally evaluated the DSS considering the entire 
cohort (n = 1904) with comparison of 10% highest ATOX1 
expression group (n = 195) vs. the lower 90% of the patient 
cohort (n = 1709) (Fig. S5). Supportive, no significant cor-
relation was detected between ATOX1 expression and sur-
vival for stage 3 tumors (48 vs. 59 months). Additionally, 
considering the entire patient cohort, the difference in sur-
vival for stage 2 patients with low vs. high ATOX1 levels 
Fig. 2  High ATOX1 expression is correlated with worse survival out-
come for specific subtypes of breast cancer disease. Disease-specific 
survival (DSS) KM curve for the different PAM50 molecular sub-
types of breast cancer patients stratified by ATOX1 expression. We 
observed a strong association between ATOX1 levels and DSS for 
patients with Normal-like (p = 0.005), Luminal A (LumA) (p = 0.002) 
and Luminal B (LumB) (p = 0.001) breast tumors
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became non-significant (p = 0.058). Stages 0 and 4 could 
not be assessed because there are only few patients with 
these stages of disease in the METABRIC data set. Thus, 
the ATOX1 expression level appears to be a determinant of 
survival only at early stages of breast cancer.
Discussion
We found that patients with high ATOX1 expression levels in 
their primary tumor have approximately 50% lower survival 
chances (median DSS decreased by a factor of 2). This sug-
gests that ATOX1 may participate in breast cancer-related 
processes leading to patient deaths. As 90% of all cancer-
related deaths are due to metastasis [8], this finding suggests 
that ATOX1 may play a crucial role in processes facilitating 
breast cancer metastasis like cancer cell migration.
Evaluation of the different PAM50 molecular subtypes 
using the METABRIC breast cancer data set shows sig-
nificant correlations between high ATOX1 expression and 
decreased DSS for Luminal A, Luminal B and Normal-like 
breast tumors, but not for Claudin low, Basal-like and HER2-
enriched tumors. However, the KM plots for OS demonstrate 
a significant relation between high ATOX1 levels and worse 
survival of patients with Claudin low subtype tumors (Fig. 
S4), thus there may be a correlation in this subtype too if 
the patient number analyzed is increased. As different sub-
types may be dominated by different oncogenic pathways, 
it is possible that ATOX1 acts in several cancer-promoting 
molecular paths leading to patient death. Nonetheless, cell 
migration, allowing for metastasis, is a common process in 
all subtypes and we earlier found that ATOX1 plays a role 
in breast cancer cell migration in cell culture studies [6], 
although the underlying pathways are not yet established.
Intriguingly, the data show ATOX1 to have prognos-
tic value in the hormone receptor-positive breast cancers 
only (and Claudin low, when considering OS). In accord, 
comparison of KM survival plots of the data divided into 
ER-positive and ER-negative tumors indicates significant 
worse survival for high ATOX1 tumors that are ER-positive 
only (p < 0.001) (Fig. S6). A potential explanation for this 
distinction is that the increased ATOX1 expression in ER-
positive tumors influences mitogen-activated protein kinase 
(MAPK) signaling, perhaps via the ATOX1–ATP7A–lysyl 
oxidase (LOX) axis [6], which in turn promotes tumor 
growth and metastasis. In support of such a link, ATOX1 
knockout in B-Raf proto-oncogene, serine/threonine kinase 
(BRAF) mutation-positive melanoma cells was found to 
reduce MAPK signaling [14]. In ER-negative tumors, other 
pathways (not dependent on ATOX1 levels) may instead 
define cancer progression [15]. We note that ER-negative 
and lymph node-positive tumors, but not ER-positive and/or 
lymph node-negative tumors, were treated with chemother-
apy (before surgery) (Fig. S2). Thus, the correlation of high 
ATOX1 levels with worse patient survival for ER-positive 
tumors only may relate to differences in treatment. Note, the 
evaluation of prognostic biomarkers using databases such 
as METABRIC and TCGA has to be carefully interpreted 
because information of the other prognostic variables such 
as stage and grade may lack in relatively a large proportion 
of patients.
Another important finding is that elevated ATOX1 
expression selectively correlates with poor survival for 
breast cancer stages 1 and 2, but not for stage 3. Likely, 
because stage 3 tumors have already spread, ATOX1 may 
not be of importance. In addition, at stage 3, the expression 
level of ATOX1 is higher on average than in stages 1 and 2 
(p = 0.037) (Fig. S7). Thus, variations between high and low 
levels may not matter at stage 3 as they may always be above 
a threshold. Notably, for stage 4, which lacked sufficient data 
for making a survival plot, the ATOX1 level appears even 
higher (Fig. S7). The role of ATOX1 in metastasis is fur-
ther supported by the observation of increased ATOX1 levels 
in lymph node-positive tumors and the fact that there is a 
Fig. 3  High ATOX1 expression is correlated with worse patient sur-
vival at early stages of breast cancer disease. Disease-specific sur-
vival (DSS) KM curve for the different stages of breast cancer disease 
stratified by ATOX1 expression. We observed a strong association for 
disease stage 1 (p = 0.008) and stage 2 (p = 0.018)
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correlation between presence of positive lymph nodes and 
worse patient prognosis (Tables S1, 2).
Taken together, our data indicate that the ATOX1 expres-
sion level can be used as a biomarker in early stages of breast 
cancer, whereby high ATOX1 levels correlate with worse 
survival prognosis in Luminal A, Luminal B and Normal-
like (and Claudin low when considering OS data) tumors. In 
such cases, Cu chelation therapy may be helpful to patients 
to prolong their lives. Further molecular-mechanistic stud-
ies of the underlying pathways, which result in ATOX1 
expression levels being correlated with breast cancer patient 
survival, may allow for the discovery of new cancer drug 
targets.
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